CEO Gilad Oren Buys $25K in Shares Following Recent Private Placement
APRE sits 47% above its 52-week low of $0.548.
Summary
Aprea Therapeutics CEO Gilad Oren purchased $25,009 in company stock at $0.89 per share, participating in a recent private placement and signaling confidence amidst delisting concerns.
Key Events · Ownership and Investor Activity · APRE
-
CEO Stock Purchase
Gilad Oren, President and CEO, acquired 56,200 shares of common stock for a total value of $25,009 on January 30, 2026.
-
Participation in Private Placement
The purchase was part of the $5.6 million private placement announced on January 29, 2026, demonstrating insider commitment to the capital raise.
-
Confidence Amidst Challenges
This insider buying follows a Nasdaq deficiency notice on January 23, 2026, and suggests management's belief in the company's ability to overcome its low stock price and maintain its listing.
-
Premium to Market
The shares were acquired at $0.89 per share, which is above the current market price of $0.8054.
Analysis · APRE · Life Sciences
Aprea Therapeutics' CEO, Gilad Oren, demonstrated confidence by purchasing $25,009 worth of common stock at $0.89 per share. This transaction is part of the $5.6 million private placement announced on January 29, 2026, in which the company raised capital. The CEO's participation in this offering, especially after the company received a Nasdaq deficiency letter on January 23, 2026, for failing to maintain a minimum bid price, signals a belief in the company's future and its ability to address current challenges. The purchase price of $0.89 is also above the current market price of $0.8054, further reinforcing a positive outlook from leadership.
At the time of this filing, APRE was trading at $0.81 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $5.3M. The 52-week trading range was $0.55 to $4.65. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.